The Children's Tumor Foundation

• NCT01419639

  Collaborator, Phase 2, Completed, 10 people, 18 Aug 2011

• Yang Hou

  Cognitive aging in middle-aged and older adults with neurofibromatosis type 1: Patterns and predictors, CTF-2023-10-002, 2023–2025, 1 Oct 2023

• Florida State University

  Cognitive aging in middle-aged and older adults with neurofibromatosis type 1: Patterns and predictors, CTF-2023-10-002, 2023–2025, 1 Oct 2023

• Center for Cancer Research

  Cognitive aging in middle-aged and older adults with neurofibromatosis type 1: Patterns and predictors, CTF-2023-10-002, 2023–2025, 1 Oct 2023

• National Cancer Institute

  Cognitive aging in middle-aged and older adults with neurofibromatosis type 1: Patterns and predictors, CTF-2023-10-002, 2023–2025, 1 Oct 2023

• National Cancer Institute

  Cognitive aging in middle-aged and older adults with neurofibromatosis type 1: Patterns and predictors, CTF-2023-10-002, 2023–2025, 1 Oct 2023

• National Institutes of Health

  Cognitive aging in middle-aged and older adults with neurofibromatosis type 1: Patterns and predictors, CTF-2023-10-002, 149.9k, 2023–2025, Lead, 1 Oct 2023

• Roope Kallionpää

  Risk factors and characteristics of NF1-associated cancer, CTF-2023-01-006, 2023–2025, 1 Jun 2023

• University of Turku

  Risk factors and characteristics of NF1-associated cancer, CTF-2023-01-006, 145.8k, 2023–2025, 1 Jun 2023

Sources: openalex.org

• Convergent molecular signatures of ageing and injury in the peripheral nervous system

  Drug Discovery Award 2015-05-010, 11 Feb 2026

Sources: api.crossref.org